Le Lézard
Classified in: Health, Science and technology
Subject: PER

Micreos appoints Joost Goderie as CFO and member of the Board of Directors

THE HAGUE, The Netherlands, Jan. 28, 2022 /PRNewswire/ -- Micreos announced that it has appointed Joost Goderie to the management board as Chief Financial Officer (CFO). Joost will be working closely together with the other members of the management team to help drive Micreos's growth and deliver its targeted antibacterial technology to the world. He will be responsible for Finance, Tax and Legal, and will coordinate the company's legal restructuring, which will result in the separation of its pharma and OTC businesses. 

Joost Goderie, CFO Micreos

Joost brings over 30 years of finance and leadership experience in various CFO and general management roles and has extensive experience in building and growing businesses. He was formerly CFO and CEO of Eurofiber, a European fiber optic communication provider, that he co-founded in 2000 and was one of the initiators and Managing Director of Rabo's Bouwfonds Communication Infrastructure Fund. 

Micreos CEO Mark Offerhaus said: "We are very pleased to welcome Joost on board. He has a strategic and practical mind, and his M&A and private equity background will be invaluable as we bring our game-changing anti-bacterial technology out to the world, in the face of the 'hidden pandemic' of antibiotic resistance." 

"I am privileged to join an innovative leadership team focused on inventing health solutions that contribute to the future of humanity. Thanks to its outstanding technology, Micreos is already the leader in the field of targeted biological therapies and I am excited to work with the team to realize the company's growth strategy and financial goals," said Joost Goderie.

About Micreos
Micreos develops targeted antibacterial technology set to replace antibiotics. Looking for safer, healthier and more sustainable solutions, the company's researchers, in close collaboration with the Swiss Federal Technology Institute ETH Zurich, turned to nature's own precision anti-bacterials, called endolysins. These highly-specific enzymes target only unwanted bacteria while preserving the microbiome, comprising of billions of 'good' bacteria essential to our health. With headquarters in The Hague, The Netherlands, Micreos runs its Endolysin Technology Centre Zurich in Wädenswil (CH) and operates three business units in The Netherlands and Switzerland: Pharma, OTC and Food. Micreos Pharma focuses on anti S. aureus endolysins for atopic dermatitis, diabetic wound infections, bloodstream infections and CTCL, a type of skin cancer associated with the colonisation of S. aureus. Gladskin is Micreos's game-changing OTC brand for people with inflammatory skin conditions such as acne, eczema and rosacea. Phageguard represents Micreos Food Safety's contribution to safer food, based on targeted prevention of dangerous food pathogens such as Salmonella and Listeria.

Micreos Logo

Photo - https://mma.prnewswire.com/media/1735806/Joost_Goderie.jpg
Logo - https://mma.prnewswire.com/media/1278645/Micreos_Logo.jpg

These press releases may also interest you

at 06:50
Cable One, Inc. (the "Company" or "Cable One") today announced that its Board of Directors has authorized a stock repurchase program of up to $450 million of Cable One's common stock. The size and timing of any purchases will depend on a number of...

at 06:50
Pfizer Inc. and BioNTech SE today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following...

at 06:50
Spire Global, Inc. ("Spire" or "the Company"), a leading global provider of space-based data, analytics and space services, today announced it was awarded a subcontract agreement with TCOM, L.P. (TCOM), the global leader in elevated intelligence,...

at 06:37
The BSV Global Blockchain Convention welcomes the public, businesses, and the industry for the first time ever in Dubai. Come to the Grand Hyatt in Dubai between 24 May and 26 May, 2022 and be part of the conversation. The convention will play host...

at 06:36
Silverbullet, today announces the successful year-one results it has delivered for the leading pub, cider and beer company, Heineken Brazil. Silverbullet has supported the brand in reaching millions of consumers through a bespoke data strategy...

at 06:35
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the Biologics License Application (BLA) for...

News published on 28 january 2022 at 03:00 and distributed by: